ASX Announcement **25 November 2026**

RECEIPT OF SECTION 249D NOTICE FROM BCAL DIAGNOSTICS

Genetic Signatures Limited (ASX: GSS) (**GSS** or the **Company**) advises in accordance with ASX Listing Rule 3.17A, that it has received another request from BCAL Diagnostics Limited (ASX: BDX) (**BCAL**) pursuant to section 249D of the *Corporations Act 2001* (Cth) for the board of directors of GSS (**Board**) to call and arrange a general meeting of shareholders for the purposes of considering the following resolution:

> *"That Michael Aicher be removed as a director of the Company effective immediately on the passing of this resolution."*

GSS notes that it presently has only three directors, and if shareholders passed the resolution to remove Michael Aicher, then GSS would only have two directors and it would be in contravention of section 201A(2) of the Corporations Act.

As such, GSS is currently considering the section 249D notice and, if it considers the notice to be valid, will comply with its relevant obligations under the Corporations Act and will undertake the necessary steps to convene a general meeting.

Additionally, the Chair is currently in discussions with a number of director candidates who may be appointed as new directors of GSS. Any such appointment would ensure that the Board continues to have the minimum number of directors required under the Corporations Act and GSS' Constitution, notwithstanding the outcome of the proposed resolution.

This announcement has been authorised for release by the Board of Genetic Signatures Limited.

– END –

For further information contact:

Mike Aicher
Chair
Genetic Signatures
info@geneticsignatures.com

About Genetic Signatures

Genetic Signatures is a specialist molecular diagnostics company focused on the development and commercialisation of its proprietary platform technology, 3base®. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the EasyScreen™ brand. Genetic Signatures' proprietary 3base® platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospital and pathology laboratories undertaking infectious disease screening.

Genetic Signatures Ltd ABN 30 095 913 205
7 Eliza Street, Newtown NSW 2042
Telephone + 61 (2) 9870 7580